Trial reportThe oncologist2010
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Trial report in The oncologist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00362986 (A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash]
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity.Investigational new drugs · 2014Trial
- Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer.Cancers · 2025Article
- EGF receptor in organ development, tissue homeostasis and regeneration.Journal of biomedical science · 2025Review
- Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2021Article
- Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.Investigational new drugs · 2021Article
- Pruritus Associated with Targeted Anticancer Therapies and Their Management.Dermatologic clinics · 2018Review
- Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.The oncologist · 2016Review
- Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.World journal of gastroenterology · 2016Review
- Skin problems and EGFR-tyrosine kinase inhibitor.Japanese journal of clinical oncology · 2016Review
- Management of Dermatologic Complications of Lung Cancer Therapies.Current treatment options in oncology · 2015Review
- Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Dermatology research and practice · 2014Review
- Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.Current treatment options in oncology · 2013Review
- A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.Radiology and oncology · 2013Article
- Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Journal of the advanced practitioner in oncology · 2012Review
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
purposeRash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes.
methodsThis placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks.
resultsFifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreen-treated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p = .20). Quality of life scores declined but remained comparable between arms.
conclusionsSunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.